Notably, ERD-3111 demonstrated superior bioavailability and achieved significant tumor regression and complete growth inhibition in wild-type and two clinically relevant ESR1-mutated (Y537S and D538G) MCF-7 xenograft models, outperforming ARV-471. This evidence concerns the gene ESR1 and neoplasm.